FDA Approved: IBRANCE — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

FDA approved a supplemental application for IBRANCE (palbociclib) from Pfizer Laboratories Div Pfizer Inc, authorizing changes to its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• IBRANCE (PALBOCICLIB)

Snippet

SUPPL AP for IBRANCE (PALBOCICLIB)